Pulegone is a minty monoterpene ketone most strongly associated with pennyroyal and present at lower levels in peppermint-type oils. Its evidence base is unusually strong for an essential-oil constituent because identity, metabolism, hepatotoxicity, and regulatory risk assessment are all well documented. For AromaForge, the right framing is compositional importance plus well-established safety caution: pulegone is a real aroma chemical with meaningful toxicology literature, not a wellness claim ingredient.
Chemical identity and composition
PubChem indexes the common natural form as (+)-/(R)-pulegone, CID 442495. In the archive, pulegone appears both as the dominant marker in pennyroyal and as a constrained minor constituent in peppermint profiles, which matches regulatory attention to cumulative exposure from mint-derived products. Human and animal metabolism literature repeatedly connects pulegone to menthofuran formation and downstream reactive intermediates.
Aroma and practical use
- Use the recorded minty, peppermint-like, camphoraceous, herbal, herbaceous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 1999 human liver CYP study found that CYP2E1, CYP1A2, and CYP2C19 oxidized pulegone to menthofuran and supported formation of a furan-epoxide-related intermediate in menthofuran metabolism.
A 1999 human liver CYP study found that CYP2E1, CYP1A2, and CYP2C19 oxidized pulegone to menthofuran and supported formation of a furan-epoxide-related intermediate in menthofuran metabolism.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
The NTP two-year gavage studies reported no evidence of carcinogenic activity in male rats or male mice, equivocal evidence in female mice, and clear evidence in female rats based on increased urinary bladder neoplasms.
The NTP two-year gavage studies reported no evidence of carcinogenic activity in male rats or male mice, equivocal evidence in female mice, and clear evidence in female rats based on increased urinary bladder neoplasms.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
JECFA's pulegone monograph summarized short-term toxicity literature around pulegone and related substances and treated metabolism to menthofuran as central to the safety evaluation.
JECFA's pulegone monograph summarized short-term toxicity literature around pulegone and related substances and treated metabolism to menthofuran as central to the safety evaluation.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedEMA's 2016 public statement set daily exposure limits for pulegone plus menthofuran in herbal medicinal products, reflecting concern about cumulative exposure from mint oils.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
Pulegone is widely treated as a hepatotoxic concern because metabolism to menthofuran and reactive intermediates has been repeatedly demonstrated.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
Because the safety literature is driven by toxicology and exposure restriction, archive copy should avoid benefit-style language for isolated pulegone.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
These are research candidates recorded in the interaction matrix. They do not add a proven-amplification bonus to the score.
MenthofuranAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
animal · effect
No source citation attached.
Read Menthofuran report →CarvoneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Carvone report →How the effects were investigated
cyp_mediated_conversion_to_menthofuran
Human liver CYP2E1, CYP1A2, and CYP2C19 oxidize pulegone to menthofuran, a proximate hepatotoxic metabolite highlighted in mechanistic toxicology studies.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
reactive_metabolite_generation
Mechanistic toxicology literature supports further oxidation of menthofuran through reactive intermediates, helping explain why pulegone hazard discussions focus on metabolic activation rather than the parent compound alone.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (7)
- The hazard literature on pulegone is much stronger than any isolated-compound benefit literature, so this record is intentionally safety-weighted.
- Human controlled exposure studies directly relevant to consumer aroma use were not located in this pass.
- Odor descriptors are well established in flavor and fragrance references, but the strongest cited sources gathered here focus on toxicology and identity rather than sensory profiling.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Interaction candidates lack an attached source citation and remain unqualified.
- Some findings lack a directly linked source; treat those entries as unverified research notes.